新闻
中国的新药获批、科研成果和医院动态，以英文发布，均附原文链接。
Digital intelligence empowers medical visits, creating people-friendly diagnosis and treatment
Beijing Anzhen Hospital is using artificial intelligence to empower smart healthcare, introducing multiple medical robots and online convenience systems to streamline visits and improve diagnosis and treatment…
政策20 Years Since Global Approval of MSD's HPV Vaccine: Multiple Parties Join Forces to Advance HPV Prevention in China
In October 2025, seven departments including the National Disease Control and Prevention Administration jointly issued a notice to include the HPV vaccine in the national immunization program starting November 10, 2025.
研究Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China
Allogeneic CD19 CAR NK-cell therapy was safe and well tolerated in relapsed or refractory systemic lupus erythematosus, with six (67%) of nine patients with more than 12 months' follow-up attaining DORIS remission and…
研究Effect of Chinese medicine compound on intestinal bifidobacteria recovery and CD4+ T-Cell activation in postoperative chemotherapy patients with breast cancer
The traditional Chinese medicine compound effectively maintained intestinal flora balance, promoted beneficial bacterial growth, reduced adverse reactions and offered better therapeutic prospects for breast cancer…
肿瘤Why Is Ovarian Cancer Often Mistaken for a Stomach Ailment? Lan Chunyan: A Silent Killer That Can Be Prevented and Treated
Over 70 percent of ovarian cancer patients are diagnosed at an advanced stage, making it a "silent killer" that is hard to catch early but can still be prevented and treated, an oncologist told Xinhua.
研究Professor Wu Hao's Team's CHOICE-RCT Study Published in JAMA Neurology—Hearing Intervention Significantly Improves Cognitive Function in the Elderly
The CHOICE-RCT study found that hearing aid intervention significantly increased the proportion of elderly patients with mild cognitive impairment whose cognitive function returned to normal (15.34% vs 2.36%), though it…
研究Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience
The GPRC5D-associated adverse events of talquetamab in Chinese patients with relapsed/refractory multiple myeloma were generally mild, well tolerated, and manageable with supportive care, consistent with the known…
肿瘤Ovarian cancer 'Chinese protocol' draws overseas patients as multidisciplinary team performs precise 'bomb disposal' for Pakistani patient
A multidisciplinary team at Fudan University Shanghai Cancer Center led by Professor Wu Xiaohua achieved R0 resection in a 60-year-old Pakistani woman with advanced ovarian cancer using a…